ticlopidine has been researched along with Atrial Fibrillation in 204 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To elucidate the efficacy and safety between aspirin and clopidogrel, a multicenter randomized controlled trial was designed in AF patients with low stroke risk." | 9.24 | Rationale and Design for a Randomized Comparison of Efficacy and Safety between Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: CESAC-AF trial. ( Bang, CS; Hong, KS; Hong, MK; Jeong, H; Jung, MH; Kim, CY; Park, SM, 2017) |
| "Dabigatran as compared to phenprocoumon has no impact on ADP-induced platelet aggregation in atrial fibrillation patients neither with nor without concomitant clopidogrel therapy." | 9.20 | Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials). ( Fiedler, AK; Kastrati, A; Martischnig, AM; Massberg, S; Mayer, K; Mehilli, J; Petzold, T; Pollak, J; Sarafoff, N; Schulz-Schüpke, S; Sibbing, D, 2015) |
| "Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage." | 9.15 | Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011) |
| "Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead." | 9.14 | Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009) |
| "In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation." | 9.13 | Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). ( Connolly, SJ; De Caterina, R; Flaker, G; Hart, RG; Healey, JS; Hohnloser, SH; Pfeffer, MA; Pogue, J; Yusuf, S, 2008) |
| "Aspirin offers modest reduction in stroke in patients with atrial fibrillation." | 9.13 | Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. ( Berger, PB; Bhatt, DL; Fox, KA; Hacke, W; Hankey, GJ; Hart, RG; Hu, T; Topol, EJ, 2008) |
| "Oral anticoagulation therapy is superior to clopidogrel plus aspirin for prevention of vascular events in patients with atrial fibrillation at high risk of stroke, especially in those already taking oral anticoagulation therapy." | 9.12 | Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. ( Chrolavicius, S; Connolly, S; Hart, R; Hohnloser, S; Pfeffer, M; Pogue, J; Yusuf, S, 2006) |
| "We evaluated the short-term safety and efficacy of aspirin-plus-clopidogrel as antithrombotic therapy in nonvalvular atrial fibrillation (AF)." | 9.11 | Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. ( Cocci, F; De Caterina, R; Lazzerini, G; Lorenzoni, R, 2004) |
| "This study was designed to investigate whether or not combination aspirin-clopidogrel therapy would reduce markers of thrombogenesis and platelet activation in atrial fibrillation (AF), in a manner similar to warfarin." | 9.10 | A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. ( Blann, AD; Chin, BS; Kamath, S; Lip, GY, 2002) |
| "Although several new antithrombotic agents have been developed for stroke prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide." | 8.88 | Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. ( Agarwal, S; Hachamovitch, R; Menon, V, 2012) |
| "Clopidogrel prevents more vascular events, including stroke, in patients with a recent myocardial infarction, stroke or peripheral vascular disease than aspirin." | 8.87 | Clopidogrel hydrogen sulphate for atrial fibrillation. ( Flaker, G; Garg, N; Rajpurohit, N, 2011) |
| "A cost-effectiveness model was constructed using data from three studies on stroke prevention in patients with contraindications: the ASAP study evaluating the Watchman device, the ACTIVE A trial of aspirin and clopidogrel, and the AVERROES trial evaluating apixaban." | 7.83 | Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. ( Akehurst, RL; Amorosi, SL; Armstrong, SO; Brereton, N; Hertz, DS; Holmes, DR; Reddy, VY, 2016) |
| "Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke." | 7.81 | Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. ( Hayashi, K; Horie, N; Izumo, T; Kaminogo, M; Nagata, I; Tsujino, A, 2015) |
| "Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)." | 7.81 | Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015) |
| "Rivaroxaban is an anticoagulant prescribed for the management of atrial fibrillation." | 7.81 | Association of rivaroxaban anticoagulation and spontaneous vitreous hemorrhage. ( Hwang, JC; Jun, JH, 2015) |
| " We analyzed the safety and efficacy of dual therapy with OAC plus clopidogrel in atrial fibrillation (AF) patients receiving drug-eluting stents (DES)." | 7.79 | Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. ( Abdel-Wahab, M; Akin, I; El-Mawardy, M; Geist, V; Richardt, G; Seivani, Y; Sulimov, DS; Toelg, R, 2013) |
| "The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear." | 7.79 | Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
| "Guidelines for atrial fibrillation (AF) recommend clopidogrel plus aspirin as an alternative stroke prevention strategy in patients in whom warfarin is unsuitable." | 7.78 | Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable. ( Anglade, MW; Coleman, CI; Kluger, J; Sobieraj, DM; Straznitskas, AD, 2012) |
| "In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding." | 7.76 | Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010) |
| "To characterize the safety of concomitant aspirin, clopidogrel, and warfarin therapy after percutaneous coronary intervention (PCI), and to identify patient characteristics that increase the risk of hemorrhage." | 7.74 | Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. ( Andrel, J; Chervoneva, I; DeCaro, M; DeEugenio, D; Duong, P; Greenspon, A; Kolman, L; Lam, L; Lee, G; McGowan, C; Ruggiero, N; Singhal, S, 2007) |
| "To elucidate the efficacy and safety between aspirin and clopidogrel, a multicenter randomized controlled trial was designed in AF patients with low stroke risk." | 5.24 | Rationale and Design for a Randomized Comparison of Efficacy and Safety between Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: CESAC-AF trial. ( Bang, CS; Hong, KS; Hong, MK; Jeong, H; Jung, MH; Kim, CY; Park, SM, 2017) |
| "Dabigatran as compared to phenprocoumon has no impact on ADP-induced platelet aggregation in atrial fibrillation patients neither with nor without concomitant clopidogrel therapy." | 5.20 | Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials). ( Fiedler, AK; Kastrati, A; Martischnig, AM; Massberg, S; Mayer, K; Mehilli, J; Petzold, T; Pollak, J; Sarafoff, N; Schulz-Schüpke, S; Sibbing, D, 2015) |
| "This prospective, randomized, multicenter study is going to assess the hypothesis that in persistent or permanent AF patients (score of CHA₂DS₂VASc≥2) after PCI-eS, the combination therapy of oral anticoagulation (warfarin) and ticagrelor (90 mg/bid) could reduce the risk of bleeding events." | 5.20 | Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS. ( Chen, L; Fu, C; Lu, W; Ma, G; Wang, Y; Yao, Y; Zuo, P, 2015) |
| "Participants in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE) trials with HF, but not randomized to oral anticoagulation, were categorized as having preserved versus reduced ejection fraction." | 5.20 | Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. ( Connolly, SJ; Hart, RG; Healey, JS; Hohnloser, SH; McAlister, FA; Pfeffer, MA; Sandhu, RK; Yuan, F; Yusuf, S, 2015) |
| "The multicenter PROTECT AF study (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) was conducted to determine whether percutaneous left atrial appendage closure with a filter device (Watchman) was noninferior to warfarin for stroke prevention in atrial fibrillation." | 5.17 | Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. ( Buchbinder, M; Doshi, SK; Halperin, JL; Holmes, D; Huber, K; Neuzil, P; Reddy, VY; Sievert, H, 2013) |
| "We selected all patients with a CHADS(2) score of 1 from the AVERROES and ACTIVE trials who were treated with acetylsalicylic acid with or without clopidogrel and calculated the incidences of ischaemic or unspecified stroke or systemic embolus (SSE) according to their CHA(2)DS(2)-VASc score." | 5.17 | The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. ( Connolly, SJ; Coppens, M; Dorian, P; Eikelboom, JW; Hart, RG; Lip, GY; Shestakovska, O; Yusuf, S, 2013) |
| "Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage." | 5.15 | Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011) |
| " In the 3371 patients randomized to vitamin K antagonists and the 3335 patients randomized to clopidogrel plus aspirin in ACTIVE-W, the hazard ratio (HR) and 95% confidence intervals (95% CIs) for subsequent death associated with the occurrence of non-fatal stroke was 5." | 5.14 | Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. ( Budaj, A; Chrolavicius, S; Connolly, SJ; De Caterina, R; Morais, J; Pogue, J; Renda, G; Yusuf, S, 2010) |
| "We genotyped patients from two large, randomized trials that showed that clopidogrel, as compared with placebo, reduced the rate of cardiovascular events (the primary efficacy outcome) among patients with acute coronary syndromes and among patients with atrial fibrillation." | 5.14 | Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. ( Anand, SS; Bhatt, DL; Connolly, SJ; Eikelboom, JW; Fox, KA; Hirsh, J; Mehta, SR; Paré, G; Simonsen, K; Yusuf, S, 2010) |
| "Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead." | 5.14 | Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009) |
| "Aspirin offers modest reduction in stroke in patients with atrial fibrillation." | 5.13 | Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. ( Berger, PB; Bhatt, DL; Fox, KA; Hacke, W; Hankey, GJ; Hart, RG; Hu, T; Topol, EJ, 2008) |
| "In a posthoc analysis, the TTRs of patients on OAC in a randomized trial of OAC versus clopidogrel plus aspirin (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE W]) were used to calculate the mean TTR for each of 526 centers and 15 countries." | 5.13 | Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. ( Commerford, P; Connolly, SJ; Eikelboom, J; Flaker, G; Franzosi, MG; Healey, JS; Pogue, J; Yusuf, S, 2008) |
| "In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation." | 5.13 | Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). ( Connolly, SJ; De Caterina, R; Flaker, G; Hart, RG; Healey, JS; Hohnloser, SH; Pfeffer, MA; Pogue, J; Yusuf, S, 2008) |
| "The ACTIVE W (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events) was a trial comparing OAC to combined antiplatelet therapy with aspirin and clopidogrel for prevention of vascular events in 6,706 AF patients." | 5.12 | Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. ( Connolly, SJ; Healey, JS; Hohnloser, SH; Pajitnev, D; Pfeffer, MA; Pogue, J; Yusuf, S, 2007) |
| "Oral anticoagulation therapy is superior to clopidogrel plus aspirin for prevention of vascular events in patients with atrial fibrillation at high risk of stroke, especially in those already taking oral anticoagulation therapy." | 5.12 | Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. ( Chrolavicius, S; Connolly, S; Hart, R; Hohnloser, S; Pfeffer, M; Pogue, J; Yusuf, S, 2006) |
| "We evaluated the short-term safety and efficacy of aspirin-plus-clopidogrel as antithrombotic therapy in nonvalvular atrial fibrillation (AF)." | 5.11 | Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. ( Cocci, F; De Caterina, R; Lazzerini, G; Lorenzoni, R, 2004) |
| "This study was designed to investigate whether or not combination aspirin-clopidogrel therapy would reduce markers of thrombogenesis and platelet activation in atrial fibrillation (AF), in a manner similar to warfarin." | 5.10 | A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. ( Blann, AD; Chin, BS; Kamath, S; Lip, GY, 2002) |
| "Clopidogrel combined with aspirin is routinely prescribed after coronary artery stenting, in patients with acute coronary syndromes, and recently to prevent stroke in patients with acute minor ischemic stroke and TIA." | 4.91 | Effect of addition of clopidogrel to aspirin on subdural hematoma: meta-analysis of randomized clinical trials. ( Bakheet, MF; Hart, RG; Pearce, LA, 2015) |
| " Patients with indications for antithrombotic therapy often will have coexisting vascular disease, such as coronary artery disease, requiring concomitant antiplatelet therapy with aspirin alone or more commonly with a dual antiplatelet regimen, aspirin and clopidogrel, or prasugrel or ticagrelor." | 4.90 | Combining antiplatelet and antithrombotic therapy (triple therapy): what are the risks and benefits? ( Alpert, JS; Asencio, LA; Huang, JJ, 2014) |
| " In patients on triple antithrombotic therapy with vitamin K antagonists, aspirin, and clopidogrel, a single clinical trial indicates that withdrawal of aspirin may reduce bleeding risk without increasing the risk of coronary thrombosis." | 4.90 | Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. ( Thompson, PL; Verheugt, FW, 2014) |
| "The role of aspirin in the early management of stroke is well established." | 4.89 | Pharmacokinetic considerations for antithrombotic therapies in stroke. ( Apostolakis, S; Lip, GY; Shantsila, E, 2013) |
| "Although several new antithrombotic agents have been developed for stroke prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide." | 4.88 | Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. ( Agarwal, S; Hachamovitch, R; Menon, V, 2012) |
| "Clopidogrel prevents more vascular events, including stroke, in patients with a recent myocardial infarction, stroke or peripheral vascular disease than aspirin." | 4.87 | Clopidogrel hydrogen sulphate for atrial fibrillation. ( Flaker, G; Garg, N; Rajpurohit, N, 2011) |
| "The use of triple therapy (warfarin plus dual antiplatelet therapy) has increased in recent years due to an aging population with a higher risk for atrial fibrillation, as well as the increased use of coronary stents for acute coronary syndromes." | 4.87 | Triple therapy in hospitalized patients: facts and controversies. ( Smetana, GW; Srour, JF, 2011) |
| " The ACTIVE-W study was a noninferiority comparison of the combination of clopidogrel and acetylsalicylic acid versus oral anticoagulant among patients with atrial fibrillation." | 4.84 | Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial. ( Cairns, JA; Gent, M; Hirsh, J; Marler, J; Pogue, J; Pritchett, EL; Wittes, J; Wyse, DG, 2008) |
| "Recent trials of antiplatelet therapy for stroke prevention indicate that the combination of clopidogrel (75 mg/d) plus low-dose aspirin (75-162 mg/d) was not more effective than low-dose aspirin alone in the long-term prevention of major vascular events among patients at high risk of atherothrombotic events, nor was it more effective than oral anticoagulation in patients with atrial fibrillation." | 4.84 | Antiplatelet therapy for stroke prevention. ( Hankey, GJ, 2007) |
| " Pooled data from trials comparing antithrombotic treatment with placebo show that warfarin reduces the risk of stroke by 62% and that aspirin alone reduces the risk by 22%." | 4.82 | [Preventing cerebrovascular accidents during atrial fibrillation]. ( Boccara, F; Cohen, A; Ederhy, S; Hammoudi, N; Janower, S; Meuleman, C, 2005) |
| "Warfarin therapy achieving an International Normalized Ratio between 2 and 3 has been shown to be effective in preventing stroke." | 4.82 | New possibilities in anticoagulant management of atrial fibrillation. ( Waldo, AL, 2004) |
| "Based on the established fact that anticoagulation with warfarin is superior to antiplatelet agents in the prevention of thromboembolic events in atrial fibrillation (AF), we propose that, in contrast to atherothrombotic disorders, the risk of developing a stroke or thromboembolic event in AF is more likely to be affected by the coagulation pathway than by platelet activity." | 4.82 | Atrial fibrillation: should we target platelets or the coagulation pathway? ( Lip, GY; Tan, KT, 2003) |
| "English-language articles published after 1977 and indexed in MEDLINE under the following Medical Subject Heading terms: anticoagulants, aspirin, dipyridamole, ticlopidine, or sulfinpyrazone, combined with cerebrovascular disorders." | 4.79 | Medical treatment for stroke prevention. ( Barnett, HJ; Feussner, JR; Matchar, DB; McCrory, DC, 1994) |
| " Due to previous atrial fibrillation and ischaemic heart disease, this patient was treated with both dabigatran and clopidogrel." | 3.88 | Left ventricular mural thrombus despite treatment with dabigatran and clopidogrel. ( Fredgart, M; Gill, S, 2018) |
| "Using the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (n = 10,135), we analyzed outcomes in patients with coronary artery disease (n = 1827) according to treatment with triple antithrombotic therapy (defined as concurrent therapy with an oral anticoagulant, a thienopyridine, and aspirin) or dual antithrombotic therapy (comprising either an oral anticoagulant and one antiplatelet agent [OAC plus AA] or 2 antiplatelet drugs and no anticoagulant [DAP])." | 3.83 | Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. ( Ansell, J; Chang, P; Fonarow, GC; Gersh, BJ; Go, AS; Hylek, EM; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Rao, M; Simon, DN; Singer, DE; Thomas, L, 2016) |
| "A cost-effectiveness model was constructed using data from three studies on stroke prevention in patients with contraindications: the ASAP study evaluating the Watchman device, the ACTIVE A trial of aspirin and clopidogrel, and the AVERROES trial evaluating apixaban." | 3.83 | Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. ( Akehurst, RL; Amorosi, SL; Armstrong, SO; Brereton, N; Hertz, DS; Holmes, DR; Reddy, VY, 2016) |
| "Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke." | 3.81 | Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. ( Hayashi, K; Horie, N; Izumo, T; Kaminogo, M; Nagata, I; Tsujino, A, 2015) |
| "Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)." | 3.81 | Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015) |
| "Secondary prevention treatment with aspirin/ clopidogrel, beta blockers, inhibitors of the rennin-angiotensin-aldosterone converting system and statins reduces the morbidity and mortality of patients after acute coronary syndrome (ACS)." | 3.81 | [SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS]. ( Elis, A; Lishner, M; Pereg, D; Yahia, DH, 2015) |
| "Rivaroxaban is an anticoagulant prescribed for the management of atrial fibrillation." | 3.81 | Association of rivaroxaban anticoagulation and spontaneous vitreous hemorrhage. ( Hwang, JC; Jun, JH, 2015) |
| "To compare the lifetime cost and effectiveness of five alternative chronic atrial fibrillation (AF) management strategies: rivaroxaban, warfarin, aspirin plus clopidogrel, aspirin and no prevention." | 3.80 | Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting. ( He, B; Kun, L; Liu, X; Wu, B, 2014) |
| " However, in patients with atrial fibrillation (AF), there is a concern that combining warfarin with dual antiplatelet therapy may increase the risk of bleeding." | 3.80 | Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents. ( Araki, T; Enomoto, Y; Hara, H; Hori, M; Iijima, R; Itaya, H; Ito, N; Nagashima, Y; Nakamura, M; Shiba, M; Sugi, K; Tokue, M; Utsunomiya, M; Yamazaki, K, 2014) |
| "Patients with atrial fibrillation (AF) often receive, in addition to warfarin, antithrombotic drugs to manage other comorbid conditions." | 3.79 | The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. ( Azoulay, L; Dell'Aniello, S; Renoux, C; Simon, T; Suissa, S, 2013) |
| "The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear." | 3.79 | Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
| " We analyzed the safety and efficacy of dual therapy with OAC plus clopidogrel in atrial fibrillation (AF) patients receiving drug-eluting stents (DES)." | 3.79 | Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. ( Abdel-Wahab, M; Akin, I; El-Mawardy, M; Geist, V; Richardt, G; Seivani, Y; Sulimov, DS; Toelg, R, 2013) |
| "Use of warfarin at discharge in patients with atrial fibrillation is greater among those with higher stroke and bleeding risks, but despite higher-risk profiles, less than half received warfarin at discharge." | 3.78 | Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. ( Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY, 2012) |
| "We compared efficacy and safety of warfarin, direct thrombin inhibitor dabigatran and clopidogrel in prevention of stroke in 210 patients with nonvalvular atrial fibrillation (AF) aged 65-80 years." | 3.78 | [Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation]. ( Kanorskiĭ, SG; Shevelev, VI, 2012) |
| " Fatal or nonfatal (requiring hospitalization) bleeding was determined according to antithrombotic treatment regimen: triple therapy (TT) with vitamin K antagonist (VKA)+aspirin+clopidogrel, VKA+antiplatelet, and dual antiplatelet therapy with aspirin+clopidogrel." | 3.78 | Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. ( Gislason, GH; Hansen, CM; Hansen, ML; Karasoy, D; Kristensen, SL; Køber, L; Lamberts, M; Olesen, JB; Ruwald, MH; Torp-Pedersen, C, 2012) |
| "We compared the efficacy and safety of warfarin, dabigartan, and clopidogrel used to prevent tromboembolism in 210 elderly patients with non-valvular atrial fibrillation depending on the age." | 3.78 | [Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation]. ( Kanorsky, SG; Shevelev, VI, 2012) |
| "Guidelines for atrial fibrillation (AF) recommend clopidogrel plus aspirin as an alternative stroke prevention strategy in patients in whom warfarin is unsuitable." | 3.78 | Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable. ( Anglade, MW; Coleman, CI; Kluger, J; Sobieraj, DM; Straznitskas, AD, 2012) |
| "Practice guidelines recommend anticoagulation therapy with warfarin for stroke prevention in patients with atrial fibrillation (AF)." | 3.78 | Warfarin use in nursing home residents: results from the 2004 national nursing home survey. ( Ghaswalla, PK; Harpe, SE; Slattum, PW, 2012) |
| "For patients with nonrheumatic AF, including those with paroxysmal AF, who are (1) at low risk of stroke (eg, CHADS(2) [congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score of 0), we suggest no therapy rather than antithrombotic therapy, and for patients choosing antithrombotic therapy, we suggest aspirin rather than oral anticoagulation or combination therapy with aspirin and clopidogrel; (2) at intermediate risk of stroke (eg, CHADS(2) score of 1), we recommend oral anticoagulation rather than no therapy, and we suggest oral anticoagulation rather than aspirin or combination therapy with aspirin and clopidogrel; and (3) at high risk of stroke (eg, CHADS(2) score of ≥ 2), we recommend oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel." | 3.78 | Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. ( Eckman, MH; Fang, MC; Go, AS; Halperin, JL; Howard, PA; Hughes, M; Hylek, EM; Lane, DA; Lip, GYH; Manning, WJ; Schulman, S; Singer, DE; Spencer, FA; You, JJ, 2012) |
| "Current American Heart Association/American Stroke Association guidelines identify warfarin use as a class IA indication in patients with atrial fibrillation (AF) and ischemic stroke (IS) or transient ischemic attack (TIA)." | 3.77 | Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry. ( Bushnell, CD; Lopes, RD; Olson, DM; Pan, W; Peterson, ED; Shah, BR; Zhao, X, 2011) |
| "In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding." | 3.76 | Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010) |
| "To characterize the safety of concomitant aspirin, clopidogrel, and warfarin therapy after percutaneous coronary intervention (PCI), and to identify patient characteristics that increase the risk of hemorrhage." | 3.74 | Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. ( Andrel, J; Chervoneva, I; DeCaro, M; DeEugenio, D; Duong, P; Greenspon, A; Kolman, L; Lam, L; Lee, G; McGowan, C; Ruggiero, N; Singhal, S, 2007) |
| "Within a cross-sectional study, nested in a cohort we identified 931 patients with a recent ischemic stroke or TIA who were discharged with OAC or with one of the antiplatelet medications aspirin, clopidogrel, or the combination of aspirin and extended-release dipyridamole." | 3.71 | Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry. ( Lalouschek, W; Lang, W; Müllner, M, 2001) |
| "Elderly men are more likely than elderly women to receive aspirin and ticlopidine and equally like to receive warfarin after a stroke." | 3.70 | Sex differences and similarities in the management and outcome of stroke patients. ( Austin, PC; Holroyd-Leduc, JM; Kapral, MK; Tu, JV, 2000) |
| "(1) In the acute phase of ischaemic stroke in patients free of thrombogenic heart disease, combined treatment with aspirin + moderate-dose unfractionated heparin reduces the risk of relapse and death." | 3.70 | Antiplatelet drugs in cardiovascular prevention: stroke: acute phase and secondary prevention. ( , 2000) |
| "Thirty patients (18 women, 12 men) with permanent or paroxysmal atrial fibrillation were treated with a new antiplatelet drug, ticlopidine, in order to study platelet aggregation behaviour, to see whether the drug prevents thromboembolisms and to observe side-effects over a period of 6 months." | 3.67 | Platelet aggregation behaviour in patients treated with ticlopidine. ( Balbarini, A; Evangelisti, L; Gherarducci, G; Giordani, R; Mariani, M; Petronio, AS; Preti, R, 1987) |
| " The emergence of new anticoagulants that offer equal or superior efficacy, greater safety and the convenience of fixed oral dosing may make warfarin the less preferred option." | 2.48 | Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. ( Halperin, JL; Varughese, CJ, 2012) |
| "About 80% of strokes have ischemic origin." | 2.43 | [Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke]. ( Szapáry, L, 2005) |
| "Approximately 7000 intracerebral hemorrhages (ICHs) annually in the US are caused by use of antithrombotic therapies." | 2.43 | Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. ( Hart, RG; Pearce, LA; Tonarelli, SB, 2005) |
| "Stroke is the most feared complication of atrial fibrillation, and the risk of stroke increases markedly with age." | 2.42 | Trials of newer approaches to anticoagulation in atrial fibrillation. ( Cooper, HA, 2004) |
| "Six years later after a left cerebral transient ischemic attack aspirin was replaced by ticlopidine." | 2.41 | [Cholestatic hepatitis as a rare side effect of therapy with ticlopidine]. ( Auer, J; Berent, R; Haidenthaler, A; Hinterholzer, G; Höbling, W; Knoflach, P, 2000) |
| "Removal of the thrombus and maze procedure were performed at the same time." | 2.40 | [A case of mobile left atrial thrombus without mitral valve disease]. ( Asada, K; Hasegawa, Y; Kodama, T; Kondou, K; Matsuyama, N; Minohara, S; Okamoto, J; Okamoto, K; Sasaki, S; Sawada, Y, 1997) |
| "Bleeding was the primary outcome." | 1.46 | Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. ( Agarwal, S; Barakat, AF; Chaudhury, P; Ellis, SG; Faza, NN; Kapadia, SR; Mentias, A; Murat Tuzcu, E; Parashar, A; Wayangankar, S, 2017) |
| "Device-related thrombus remains a major concern because it may result in recurrent embolic events." | 1.46 | WATCHMAN device-related thrombus successfully treated with apixaban: A case report. ( Chan, PH; Kwok, OH; Lam, CC; Lam, YY; Siu, CW; Wong, CK, 2017) |
| "Aspirin (53." | 1.43 | Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience. ( Fahed, E; Ghauche, J; Maarrawi, J; Menassa-Moussa, L; Moussa, R; Nohra, G; Okais, N; Rahme, R; Rizk, T; Samaha, E, 2016) |
| " Use of β-adrenergic blockers is recommended in most guidelines, but the clinical trials to support this recommendation were performed more than 30 years ago, and routine long-term use may not be relevant to modern treatment, except when there is cardiac failure or left ventricular dysfunction." | 1.40 | Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome. ( Judkins, C; Thompson, AG; Thompson, PL, 2014) |
| " Primary end point was the combined incidence of major adverse coronary events and major bleedings." | 1.36 | Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel. ( Di Sciascio, G; Irini, D; Pasceri, V; Patti, G; Pelliccia, F; Pristipino, C; Roncella, A; Speciale, G; Varveri, A, 2010) |
| "Although saddle embolism is a relatively rare event, orthopaedic surgeons should be aware of this condition." | 1.33 | Saddle embolism after corrective femoral osteotomy: a case report. ( Hoshino, Y; Kariya, Y; Konishi, H; Noguchi, K; Ohashi, Y; Sekiya, H, 2006) |
| "Aspirin treatment for primary prevention is safe and useful at an annual coronary event risk > or = 1." | 1.32 | [Anticoagulation and antiaggregation in cardiac patients]. ( Meyer, BJ, 2003) |
| "The ER of the ball thrombus type group, especially the MB group, was very high in spite of therapy with anti-coagulants and/or anti-platelet agents, and such patients should be treated by early surgical intervention." | 1.32 | Embolic attack in patients with atrial fibrillation and atrial thrombus depends on the character of the thrombus. ( Abe, Y; Asakura, T; Gotou, J; Ishikawa, S; Iwai, M; Maehara, K; Maruyama, Y; Muroi, S; Nagata, K; Ono, M; Saitoh, F; Sakabe, A; Sakamoto, N; Sando, M; Satoh, M; Suzuki, S; Watanabe, Y, 2003) |
| "Among 801 patients not receiving treatment for thromboembolism, the annual rate was 0." | 1.30 | [Atrial fibrillation and thromboembolism: a multicenter cooperative study. Research Group for Antiarrhythmic Drug Therapy]. ( , 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.49) | 18.7374 |
| 1990's | 9 (4.41) | 18.2507 |
| 2000's | 70 (34.31) | 29.6817 |
| 2010's | 123 (60.29) | 24.3611 |
| 2020's | 1 (0.49) | 2.80 |
| Authors | Studies |
|---|---|
| Baturina, O | 1 |
| Andreev, D | 1 |
| Fedina, L | 1 |
| Mirzaev, K | 1 |
| Ivashchenko, D | 1 |
| Ryzhikova, K | 1 |
| Grishina, E | 1 |
| Bochkov, P | 1 |
| Shevchenko, R | 1 |
| Sychev, D | 1 |
| Melkonian, M | 1 |
| Jarzebowski, W | 1 |
| Pautas, E | 1 |
| Siguret, V | 1 |
| Belmin, J | 1 |
| Lafuente-Lafuente, C | 1 |
| Pareek, M | 1 |
| Bhatt, DL | 6 |
| Ten Berg, JM | 4 |
| Kristensen, SD | 1 |
| Grove, EL | 1 |
| Choi, HI | 1 |
| Ahn, JM | 1 |
| Kang, SH | 1 |
| Lee, PH | 1 |
| Kang, SJ | 1 |
| Lee, SW | 1 |
| Kim, YH | 1 |
| Lee, CW | 1 |
| Park, SW | 1 |
| Park, DW | 1 |
| Park, SJ | 1 |
| Park, SM | 1 |
| Jeong, H | 1 |
| Jung, MH | 1 |
| Hong, KS | 1 |
| Hong, MK | 1 |
| Bang, CS | 1 |
| Kim, CY | 1 |
| Yuan, C | 1 |
| Zhong, L | 1 |
| Huang, RC | 1 |
| Cannon, CP | 2 |
| Oldgren, J | 1 |
| Lip, GYH | 4 |
| Ellis, SG | 2 |
| Kimura, T | 1 |
| Maeng, M | 1 |
| Merkely, B | 1 |
| Zeymer, U | 2 |
| Gropper, S | 1 |
| Nordaby, M | 1 |
| Kleine, E | 1 |
| Harper, R | 1 |
| Manassie, J | 1 |
| Januzzi, JL | 1 |
| Steg, PG | 1 |
| Hohnloser, SH | 6 |
| Wong, CK | 1 |
| Chan, PH | 1 |
| Lam, CC | 1 |
| Kwok, OH | 1 |
| Lam, YY | 1 |
| Siu, CW | 1 |
| Duerschmied, D | 1 |
| Brachmann, J | 1 |
| Darius, H | 1 |
| Frey, N | 1 |
| Katus, HA | 1 |
| Rottbauer, W | 1 |
| Schäfer, A | 1 |
| Thiele, H | 1 |
| Bode, C | 2 |
| Fredgart, M | 1 |
| Gill, S | 1 |
| Nietlispach, F | 1 |
| Gloekler, S | 1 |
| Krause, R | 1 |
| Shakir, S | 1 |
| Schmid, M | 1 |
| Khattab, AA | 1 |
| Wenaweser, P | 1 |
| Windecker, S | 1 |
| Meier, B | 1 |
| Stiefelhagen, P | 3 |
| Tanrıkulu, A | 1 |
| Ağırbaşlı, M | 1 |
| Lamberts, M | 5 |
| Gislason, GH | 4 |
| Olesen, JB | 3 |
| Kristensen, SL | 2 |
| Schjerning Olsen, AM | 1 |
| Mikkelsen, A | 1 |
| Christensen, CB | 1 |
| Lip, GY | 16 |
| Køber, L | 4 |
| Torp-Pedersen, C | 4 |
| Hansen, ML | 6 |
| Apostolakis, S | 2 |
| Shantsila, E | 2 |
| Seivani, Y | 1 |
| Abdel-Wahab, M | 1 |
| Geist, V | 1 |
| Richardt, G | 1 |
| Sulimov, DS | 1 |
| El-Mawardy, M | 1 |
| Toelg, R | 1 |
| Akin, I | 1 |
| Steinberg, BA | 1 |
| Kim, S | 1 |
| Piccini, JP | 6 |
| Fonarow, GC | 3 |
| Lopes, RD | 7 |
| Thomas, L | 3 |
| Ezekowitz, MD | 1 |
| Ansell, J | 2 |
| Kowey, P | 2 |
| Singer, DE | 4 |
| Gersh, B | 1 |
| Mahaffey, KW | 4 |
| Hylek, E | 1 |
| Go, AS | 4 |
| Chang, P | 2 |
| Peterson, ED | 6 |
| McCormack, T | 1 |
| Suh, SY | 1 |
| Kang, WC | 1 |
| Oh, PC | 1 |
| Choi, H | 1 |
| Moon, CI | 1 |
| Lee, K | 1 |
| Han, SH | 1 |
| Ahn, T | 1 |
| Choi, IS | 1 |
| Shin, EK | 1 |
| Wu, B | 1 |
| Kun, L | 1 |
| Liu, X | 1 |
| He, B | 1 |
| Stevens, SR | 1 |
| White, HD | 2 |
| Nessel, CC | 1 |
| Goodman, SG | 1 |
| Patel, MR | 1 |
| Becker, RC | 1 |
| Halperin, JL | 5 |
| Hacke, W | 4 |
| Hankey, GJ | 4 |
| Califf, RM | 1 |
| Fox, KA | 6 |
| Breithardt, G | 1 |
| Enomoto, Y | 1 |
| Iijima, R | 1 |
| Tokue, M | 1 |
| Ito, N | 1 |
| Nagashima, Y | 1 |
| Araki, T | 1 |
| Yamazaki, K | 1 |
| Utsunomiya, M | 1 |
| Hori, M | 1 |
| Itaya, H | 1 |
| Shiba, M | 1 |
| Hara, H | 1 |
| Nakamura, M | 1 |
| Sugi, K | 1 |
| Lassen, JF | 1 |
| Mikkelsen, AP | 1 |
| Sørensen, R | 2 |
| Rubboli, A | 4 |
| Schlitt, A | 4 |
| Kiviniemi, T | 2 |
| Biancari, F | 2 |
| Karjalainen, PP | 1 |
| Valencia, J | 1 |
| Laine, M | 1 |
| Kirchhof, P | 2 |
| Niemelä, M | 2 |
| Vikman, S | 2 |
| Airaksinen, KE | 3 |
| Ice, DS | 1 |
| Shapiro, TA | 1 |
| Gnall, EM | 1 |
| Kowey, PR | 1 |
| Asencio, LA | 1 |
| Huang, JJ | 1 |
| Alpert, JS | 1 |
| Lee, J | 1 |
| Burke, DT | 1 |
| Llull, L | 1 |
| Martín, V | 1 |
| Vidal, B | 1 |
| Cervera, A | 1 |
| Thompson, PL | 2 |
| Verheugt, FW | 7 |
| Dewilde, WJ | 2 |
| Janssen, PW | 2 |
| Storey, RF | 2 |
| Adriaenssens, T | 2 |
| Verma, A | 1 |
| Cairns, JA | 2 |
| Mitchell, LB | 1 |
| Macle, L | 1 |
| Stiell, IG | 1 |
| Gladstone, D | 1 |
| McMurtry, MS | 1 |
| Connolly, S | 3 |
| Cox, JL | 1 |
| Dorian, P | 2 |
| Ivers, N | 1 |
| Leblanc, K | 1 |
| Nattel, S | 1 |
| Healey, JS | 6 |
| Thompson, AG | 1 |
| Judkins, C | 1 |
| Braun, OÖ | 1 |
| Bico, B | 1 |
| Chaudhry, U | 1 |
| Wagner, H | 1 |
| Koul, S | 1 |
| Tydén, P | 1 |
| Scherstén, F | 1 |
| Jovinge, S | 1 |
| Svensson, PJ | 1 |
| Gustav Smith, J | 1 |
| van der Pals, J | 1 |
| Bakheet, MF | 1 |
| Pearce, LA | 2 |
| Hart, RG | 11 |
| Lu, W | 1 |
| Chen, L | 1 |
| Wang, Y | 1 |
| Yao, Y | 1 |
| Fu, C | 1 |
| Zuo, P | 1 |
| Ma, G | 1 |
| Dzeshka, MS | 1 |
| Brown, RA | 1 |
| Sandhu, RK | 1 |
| Pfeffer, MA | 3 |
| Yuan, F | 1 |
| Yusuf, S | 12 |
| Connolly, SJ | 12 |
| McAlister, FA | 1 |
| Capodanno, D | 1 |
| Horie, N | 1 |
| Kaminogo, M | 1 |
| Izumo, T | 1 |
| Hayashi, K | 1 |
| Tsujino, A | 1 |
| Nagata, I | 1 |
| Angoulvant, D | 1 |
| Villejoubert, O | 1 |
| Bejan-Angoulvant, T | 1 |
| Ivanes, F | 1 |
| Saint Etienne, C | 1 |
| Fauchier, L | 1 |
| Gibson, CM | 1 |
| Mehran, R | 1 |
| Halperin, J | 1 |
| Verheugt, F | 1 |
| Wildgoose, P | 1 |
| van Eickels, M | 1 |
| Cohen, M | 1 |
| Husted, S | 1 |
| Peterson, E | 1 |
| Fox, K | 1 |
| Vavuranakis, M | 1 |
| Kalogeras, K | 1 |
| Vrachatis, D | 1 |
| Kariori, M | 1 |
| Moldovan, C | 1 |
| Mpei, E | 1 |
| Lavda, M | 1 |
| Kolokathis, AM | 1 |
| Siasos, G | 1 |
| Tousoulis, D | 1 |
| Gao, F | 2 |
| Shen, H | 2 |
| Wang, ZJ | 2 |
| Yang, SW | 2 |
| Liu, XL | 2 |
| Zhou, YJ | 2 |
| Blann, AD | 2 |
| Skjøth, F | 1 |
| Rasmussen, LH | 1 |
| Larsen, TB | 1 |
| Agewall, S | 1 |
| Huber, K | 2 |
| Jun, JH | 1 |
| Hwang, JC | 1 |
| Yahia, DH | 1 |
| Pereg, D | 1 |
| Lishner, M | 1 |
| Elis, A | 1 |
| Martischnig, AM | 1 |
| Mehilli, J | 1 |
| Pollak, J | 1 |
| Petzold, T | 1 |
| Fiedler, AK | 1 |
| Mayer, K | 1 |
| Schulz-Schüpke, S | 1 |
| Sibbing, D | 1 |
| Massberg, S | 1 |
| Kastrati, A | 1 |
| Sarafoff, N | 1 |
| Di Pasquale, G | 1 |
| Fabiaña, N | 1 |
| Ramaswami, AP | 1 |
| Ang, ES | 1 |
| De Silva, DA | 1 |
| Pankert, M | 1 |
| Salaun, E | 1 |
| Cuisset, T | 1 |
| Bonnet, JL | 1 |
| Ketterer, U | 1 |
| D'Ancona, G | 1 |
| Siegel, I | 1 |
| Ortak, J | 1 |
| Ince, H | 1 |
| Kische, S | 1 |
| Rao, M | 1 |
| Simon, DN | 1 |
| Gersh, BJ | 1 |
| Hylek, EM | 2 |
| Sambola, A | 1 |
| Mutuberría, M | 1 |
| García Del Blanco, B | 1 |
| Alonso, A | 1 |
| Barrabés, JA | 1 |
| Bueno, H | 1 |
| Alfonso, F | 1 |
| Cequier, A | 1 |
| Zueco, J | 1 |
| Rodríguez-Leor, O | 1 |
| Tornos, P | 1 |
| García-Dorado, D | 1 |
| Reddy, VY | 2 |
| Akehurst, RL | 1 |
| Armstrong, SO | 1 |
| Amorosi, SL | 1 |
| Brereton, N | 1 |
| Hertz, DS | 1 |
| Holmes, DR | 1 |
| Zhang, N | 1 |
| Chen, KY | 1 |
| Zhao, J | 1 |
| Xu, G | 1 |
| Li, G | 1 |
| Liu, T | 1 |
| Faza, NN | 1 |
| Mentias, A | 1 |
| Parashar, A | 1 |
| Chaudhury, P | 1 |
| Barakat, AF | 1 |
| Agarwal, S | 2 |
| Wayangankar, S | 1 |
| Murat Tuzcu, E | 1 |
| Kapadia, SR | 1 |
| Hoshi, T | 1 |
| Sato, A | 1 |
| Nogami, A | 1 |
| Gosho, M | 1 |
| Aonuma, K | 1 |
| Jackson, LR | 1 |
| Cyr, DD | 1 |
| Roe, MT | 2 |
| Neely, ML | 1 |
| Martinez, F | 1 |
| Lüscher, TF | 2 |
| Winters, KJ | 1 |
| Armstrong, PW | 1 |
| Prabhakaran, D | 1 |
| Magnus Ohman, E | 1 |
| Corbalán, R | 1 |
| Dugo, D | 1 |
| Bordignon, S | 1 |
| Konstantinou, A | 1 |
| Perrotta, L | 1 |
| Fürnkranz, A | 1 |
| Chun, JK | 1 |
| Schmidt, B | 1 |
| Fahed, E | 1 |
| Ghauche, J | 1 |
| Rahme, R | 1 |
| Okais, N | 1 |
| Samaha, E | 1 |
| Nohra, G | 1 |
| Rizk, T | 1 |
| Maarrawi, J | 1 |
| Menassa-Moussa, L | 1 |
| Moussa, R | 1 |
| Collet, JP | 1 |
| Guedeney, P | 1 |
| Montalescot, G | 1 |
| Buck, J | 1 |
| Kaboli, P | 1 |
| Gage, BF | 1 |
| Cram, P | 1 |
| Vaughan Sarrazin, MS | 1 |
| Wändell, P | 1 |
| Carlsson, AC | 1 |
| Holzmann, M | 1 |
| Ärnlöv, J | 1 |
| Johansson, SE | 1 |
| Sundquist, J | 1 |
| Sundquist, K | 1 |
| Jolly, SS | 1 |
| Natarajan, MK | 1 |
| Jalal, Z | 1 |
| Dinet, ML | 1 |
| Combes, N | 1 |
| Pillois, X | 1 |
| Renou, P | 1 |
| Sibon, I | 1 |
| Iriart, X | 1 |
| Thambo, JB | 1 |
| Reiner, MF | 1 |
| Breitenstein, A | 1 |
| Holy, EW | 1 |
| Glanzmann, M | 1 |
| Amstalden, H | 1 |
| Stämpfli, SF | 1 |
| Bonetti, NR | 1 |
| Falk, V | 1 |
| Keller, S | 1 |
| Savarese, G | 1 |
| Benussi, S | 1 |
| Maisano, F | 1 |
| Beer, JH | 1 |
| Steffel, J | 1 |
| Camici, GG | 1 |
| Buerke, M | 2 |
| Eeckhout, E | 1 |
| Freedman, SB | 1 |
| Gershlick, AH | 1 |
| Tse, HF | 1 |
| Manzano-Fernández, S | 1 |
| Pastor, FJ | 1 |
| Marín, F | 1 |
| Cambronero, F | 1 |
| Caro, C | 1 |
| Pascual-Figal, DA | 1 |
| Garrido, IP | 1 |
| Pinar, E | 1 |
| Valdés, M | 1 |
| Maegdefessel, L | 2 |
| Faerber, J | 1 |
| Bond, SP | 1 |
| Messow, CM | 1 |
| Raaz, U | 1 |
| Werdan, K | 1 |
| Muenzel, T | 1 |
| Weiss, C | 1 |
| Pogue, J | 8 |
| Eikelboom, J | 1 |
| Flaker, G | 4 |
| Commerford, P | 1 |
| Franzosi, MG | 2 |
| Pfeffer, M | 4 |
| Chrolavicius, S | 4 |
| Boysen, G | 1 |
| Preobrazhenskiĭ, DV | 2 |
| Hoppe, UC | 2 |
| Einecke, D | 1 |
| Pisters, R | 2 |
| Dinh, T | 1 |
| Crijns, HJ | 2 |
| Chua, D | 1 |
| Legal, M | 1 |
| Shalansky, SJ | 1 |
| Lee, YE | 1 |
| DeZee, KJ | 1 |
| Goldstein, LB | 1 |
| Richard, T | 1 |
| Butaffuoco, F | 1 |
| Vanhaeverbeek, M | 1 |
| Shalimar, S | 1 |
| Pangtey, GS | 1 |
| Singh, KK | 1 |
| Depta, JP | 1 |
| Zhao, X | 2 |
| Peacock, WF | 1 |
| Seet, RC | 1 |
| Chen, CP | 1 |
| Lane, DA | 2 |
| Lee, TH | 1 |
| Wandeler-Meyer, K | 1 |
| Bremerich, J | 1 |
| Christ, M | 1 |
| Pasceri, V | 1 |
| Patti, G | 1 |
| Pristipino, C | 1 |
| Pelliccia, F | 1 |
| Irini, D | 1 |
| Varveri, A | 1 |
| Roncella, A | 1 |
| Di Sciascio, G | 1 |
| Speciale, G | 1 |
| Laufs, U | 1 |
| Rosenkranz, S | 1 |
| Böhm, M | 1 |
| Diener, HC | 1 |
| Endres, M | 1 |
| Grond, M | 1 |
| Meinertz, T | 2 |
| Ringelstein, EB | 1 |
| Röther, J | 1 |
| Dichgans, M | 1 |
| Nie, B | 1 |
| Yan, ZX | 1 |
| Jia, de A | 1 |
| Yu, M | 1 |
| Azuma, J | 1 |
| Tsao, PS | 1 |
| Paikin, JS | 1 |
| Mehta, SR | 3 |
| Eikelboom, JW | 5 |
| Samama, MM | 1 |
| Horellou, MH | 1 |
| Achkar, A | 1 |
| Conard, J | 1 |
| De Caterina, R | 7 |
| Budaj, A | 2 |
| Morais, J | 2 |
| Renda, G | 3 |
| Clausen, MT | 1 |
| Fog-Petersen, ML | 1 |
| Raunsø, J | 1 |
| Gadsbøll, N | 1 |
| Folke, F | 1 |
| Andersen, SS | 1 |
| Schramm, TK | 1 |
| Abildstrøm, SZ | 1 |
| Poulsen, HE | 1 |
| Paré, G | 2 |
| Anand, SS | 2 |
| Hirsh, J | 3 |
| Simonsen, K | 1 |
| Geisler, T | 1 |
| Bigalke, B | 1 |
| Schwab, M | 1 |
| Srour, JF | 1 |
| Smetana, GW | 1 |
| Khan, M | 2 |
| Kamal, AK | 2 |
| Ziegelstein, RC | 1 |
| Green, A | 1 |
| Sauder, M | 1 |
| Garg, N | 1 |
| Rajpurohit, N | 1 |
| Clem, JR | 1 |
| Chaturvedi, S | 1 |
| Bhattacharya, P | 1 |
| Shah, BR | 1 |
| Olson, DM | 1 |
| Pan, W | 1 |
| Bushnell, CD | 1 |
| Cardona, L | 1 |
| Ana, G | 1 |
| Luísa, B | 1 |
| Leal, A | 1 |
| António, F | 1 |
| Lídia, S | 1 |
| Cruz, FR | 1 |
| Rodríguez-Yáñez, M | 1 |
| Arias-Rivas, S | 1 |
| Fernández-Ferro, J | 1 |
| Leira, R | 1 |
| Castillo, J | 1 |
| Blanco, M | 1 |
| Messinger-Rapport, BJ | 1 |
| Morley, JE | 1 |
| Thomas, DR | 1 |
| Gammack, JK | 1 |
| Ng, J | 1 |
| Hohnloser, S | 4 |
| Fang, MC | 2 |
| Almadi, MA | 1 |
| Barkun, A | 1 |
| Brophy, J | 1 |
| Mrdovic, I | 1 |
| Savic, L | 1 |
| Krljanac, G | 1 |
| Perunicic, J | 1 |
| Asanin, M | 1 |
| Lasica, R | 1 |
| Antonijevic, N | 1 |
| Kocev, N | 1 |
| Marinkovic, J | 1 |
| Vasiljevic, Z | 1 |
| Ostojic, M | 1 |
| Coleman, CI | 1 |
| Straznitskas, AD | 1 |
| Sobieraj, DM | 1 |
| Kluger, J | 1 |
| Anglade, MW | 1 |
| Ghaswalla, PK | 1 |
| Harpe, SE | 1 |
| Slattum, PW | 1 |
| Belousov, IuB | 1 |
| Mareev, VIu | 1 |
| Iavelov, IS | 1 |
| Belousov, DIu | 1 |
| Afanas'eva, EV | 1 |
| You, JJ | 1 |
| Howard, PA | 1 |
| Eckman, MH | 1 |
| Schulman, S | 1 |
| Hughes, M | 1 |
| Spencer, FA | 1 |
| Manning, WJ | 1 |
| Ross, S | 1 |
| Hachamovitch, R | 1 |
| Menon, V | 1 |
| Karjalainen, P | 1 |
| Pietilä, M | 1 |
| Ylitalo, A | 1 |
| Puurunen, M | 1 |
| Lewis, JP | 1 |
| Shuldiner, AR | 1 |
| Fosbol, EL | 1 |
| Wang, TY | 2 |
| Li, S | 1 |
| Shah, B | 1 |
| Mills, RM | 1 |
| Klaskala, W | 1 |
| Alexander, KP | 3 |
| Varughese, CJ | 1 |
| Petrie, C | 1 |
| Li, L | 1 |
| Granger, CB | 2 |
| Foody, JM | 1 |
| Funk, M | 1 |
| Shevelev, VI | 2 |
| Kanorskiĭ, SG | 1 |
| Ruwald, MH | 1 |
| Hansen, CM | 1 |
| Karasoy, D | 1 |
| Vavalle, JP | 1 |
| Rao, SV | 1 |
| Ten Cate, H | 1 |
| Coppens, M | 1 |
| Shestakovska, O | 1 |
| Hess, CN | 1 |
| Broderick, S | 1 |
| Newby, LK | 1 |
| Shaw, LK | 1 |
| Alexander, JH | 1 |
| Kozan, Ö | 1 |
| Kanorsky, SG | 1 |
| Azoulay, L | 1 |
| Dell'Aniello, S | 1 |
| Simon, T | 1 |
| Renoux, C | 1 |
| Suissa, S | 1 |
| Doshi, SK | 1 |
| Sievert, H | 1 |
| Buchbinder, M | 1 |
| Neuzil, P | 1 |
| Holmes, D | 1 |
| Kamath, S | 1 |
| Chin, BS | 1 |
| Ono, A | 1 |
| Fujita, T | 1 |
| Abe, Y | 1 |
| Asakura, T | 1 |
| Sakamoto, N | 1 |
| Ishikawa, S | 1 |
| Muroi, S | 1 |
| Saitoh, F | 1 |
| Satoh, M | 1 |
| Suzuki, S | 1 |
| Ono, M | 1 |
| Sakabe, A | 1 |
| Iwai, M | 1 |
| Sando, M | 1 |
| Gotou, J | 1 |
| Watanabe, Y | 1 |
| Nagata, K | 1 |
| Maehara, K | 1 |
| Maruyama, Y | 1 |
| Meyer, BJ | 1 |
| Watters, K | 1 |
| McConn Walsh, R | 1 |
| Lidell, C | 1 |
| Svedberg, LE | 1 |
| Lindell, P | 1 |
| Bandh, S | 1 |
| Job, B | 1 |
| Wallentin, L | 1 |
| Jessup, DB | 1 |
| Coletti, AT | 1 |
| Muhlestein, JB | 1 |
| Barry, WH | 1 |
| Shean, FC | 1 |
| Whisenant, BK | 1 |
| Cooper, HA | 1 |
| Di Micco, B | 1 |
| Di Micco, G | 1 |
| Niglio, A | 1 |
| Romano, M | 1 |
| Di Micco, P | 1 |
| Tan, KT | 1 |
| Lorenzoni, R | 1 |
| Lazzerini, G | 1 |
| Cocci, F | 1 |
| Waldo, AL | 1 |
| Jackson, SL | 1 |
| Peterson, GM | 1 |
| Bereznicki, LR | 1 |
| Tonarelli, SB | 1 |
| Veloso, HH | 1 |
| de Paola, AA | 1 |
| Ederhy, S | 1 |
| Meuleman, C | 1 |
| Hammoudi, N | 1 |
| Janower, S | 1 |
| Boccara, F | 1 |
| Cohen, A | 1 |
| Szapáry, L | 1 |
| Steinbeck, G | 1 |
| Hart, R | 2 |
| Camm, J | 1 |
| Commerford, PJ | 1 |
| Flather, M | 1 |
| Joyner, C | 1 |
| Anand, I | 1 |
| Arthur, H | 1 |
| Avezum, A | 1 |
| Bethala-Sithya, M | 1 |
| Blumenthal, M | 1 |
| Ceremuzynski, L | 1 |
| Diaz, R | 1 |
| Frangin, G | 1 |
| Gaudin, C | 1 |
| Golitsyn, S | 1 |
| Goldhaber, S | 1 |
| Granger, C | 1 |
| Halon, D | 1 |
| Hermosillo, A | 1 |
| Hunt, D | 1 |
| Jansky, P | 1 |
| Karatzas, N | 1 |
| Keltai, M | 1 |
| Lanas, F | 1 |
| Lau, CP | 1 |
| Le Heuzey, JY | 1 |
| Lewis, BS | 1 |
| Morillo, C | 1 |
| Oto, A | 1 |
| Paolasso, E | 1 |
| Peters, RJ | 1 |
| Pfisterer, M | 1 |
| Piegas, L | 1 |
| Pipillis, T | 1 |
| Proste, C | 1 |
| Sitkei, E | 1 |
| Swedberg, K | 1 |
| Synhorst, D | 1 |
| Talajic, M | 1 |
| Trégou, V | 1 |
| Valentin, V | 1 |
| van Mieghem, W | 1 |
| Weintraub, W | 1 |
| Varigos, J | 1 |
| Sekiya, H | 1 |
| Noguchi, K | 1 |
| Ohashi, Y | 1 |
| Kariya, Y | 1 |
| Hoshino, Y | 1 |
| Konishi, H | 1 |
| Helft, G | 1 |
| Gilard, M | 1 |
| Le Feuvre, C | 1 |
| Zaman, AG | 1 |
| Karpha, M | 1 |
| Cheng, Hy | 1 |
| DeEugenio, D | 1 |
| Kolman, L | 1 |
| DeCaro, M | 2 |
| Andrel, J | 1 |
| Chervoneva, I | 1 |
| Duong, P | 1 |
| Lam, L | 1 |
| McGowan, C | 1 |
| Lee, G | 1 |
| Ruggiero, N | 1 |
| Singhal, S | 1 |
| Greenspon, A | 1 |
| Zimarino, M | 1 |
| Cid, AR | 1 |
| Zorio, E | 1 |
| Haya, S | 1 |
| Zúñiga, P | 1 |
| Rueda, J | 1 |
| Casaña, P | 1 |
| Cabrera, N | 1 |
| Arnau, MA | 1 |
| Aznar, JA | 1 |
| Pajitnev, D | 1 |
| Wittes, J | 1 |
| Wyse, DG | 1 |
| Gent, M | 1 |
| Marler, J | 1 |
| Pritchett, EL | 1 |
| Berger, PB | 1 |
| Hu, T | 1 |
| Topol, EJ | 1 |
| Matchar, DB | 1 |
| McCrory, DC | 1 |
| Barnett, HJ | 1 |
| Feussner, JR | 1 |
| Solomon, DH | 1 |
| Dewarrat, A | 1 |
| Bogousslavsky, J | 1 |
| Matsuyama, N | 1 |
| Asada, K | 1 |
| Kondou, K | 1 |
| Kodama, T | 1 |
| Minohara, S | 1 |
| Hasegawa, Y | 1 |
| Sawada, Y | 1 |
| Okamoto, J | 1 |
| Okamoto, K | 1 |
| Sasaki, S | 1 |
| Ferguson, JJ | 1 |
| Gonzalez, ER | 1 |
| Kannel, WB | 1 |
| Olin, JW | 1 |
| Raps, EC | 1 |
| Dyken, ML | 1 |
| Benavente, O | 1 |
| Holroyd-Leduc, JM | 1 |
| Kapral, MK | 1 |
| Austin, PC | 1 |
| Tu, JV | 1 |
| Berent, R | 1 |
| Hinterholzer, G | 1 |
| Höbling, W | 1 |
| Auer, J | 1 |
| Haidenthaler, A | 1 |
| Knoflach, P | 1 |
| Lalouschek, W | 1 |
| Lang, W | 1 |
| Müllner, M | 1 |
| Uchiyama, S | 1 |
| Yamazaki, M | 1 |
| Iwata, M | 1 |
| Petronio, AS | 1 |
| Evangelisti, L | 1 |
| Preti, R | 1 |
| Gherarducci, G | 1 |
| Balbarini, A | 1 |
| Giordani, R | 1 |
| Mariani, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Efficacy and Safety Between Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk[NCT02960126] | Phase 3 | 1,500 participants (Anticipated) | Interventional | 2016-11-30 | Not yet recruiting | ||
| CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2018-05-01 | Recruiting | |||
| A Prospective Randomised, Open Label, Blinded Endpoint (PROBE) Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110mg and 150mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 - 3.0) Plus C[NCT02164864] | Phase 3 | 2,725 participants (Actual) | Interventional | 2014-07-22 | Completed | ||
| Comparison of Clinical Outcomes After Left Atrial Appendage Closure or Oral Anticoagulation in Patients With Atrial Fibrillation: A Retrospective Propensity Matched Study[NCT02787525] | 1,000 participants (Actual) | Observational | 2016-07-31 | Completed | |||
| Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)[NCT01165710] | 10,179 participants (Actual) | Observational | 2010-06-30 | Completed | |||
| A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure[NCT03088072] | Phase 4 | 75 participants (Anticipated) | Interventional | 2017-03-23 | Recruiting | ||
| Management of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting: A Multicenter, Prospective Registry[NCT00596570] | 996 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| Pharmacokinetics and Pharmacodynamics of Apixaban in End-stage Renal Disease Patients on Hemodialysis[NCT02672709] | Phase 4 | 7 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| The Effect of Nurse Practitioner-Led Care on Health Related Quality Of Life in Adult Patients With Atrial Fibrillation - A Randomized Trial[NCT02745236] | 150 participants (Actual) | Interventional | 2016-07-31 | Completed | |||
| Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial[NCT02206815] | Phase 4 | 296 participants (Actual) | Interventional | 2014-09-19 | Completed | ||
| An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention[NCT01830543] | Phase 3 | 2,124 participants (Actual) | Interventional | 2013-05-10 | Completed | ||
| Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention[NCT02334254] | Phase 4 | 420 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES Trial[NCT03568890] | Phase 4 | 510 participants (Anticipated) | Interventional | 2018-09-01 | Recruiting | ||
| Ongoing WARfarin and Coronary STENTing. A Multi-center, Prospective Registry on Antithrombotic Treatment.[NCT00722319] | 1,000 participants (Anticipated) | Observational | 2009-03-31 | Active, not recruiting | |||
| Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting[NCT00776633] | Phase 4 | 614 participants (Actual) | Interventional | 2008-09-30 | Active, not recruiting | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794] | Phase 4 | 222 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00249873] | Phase 3 | 7,554 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298] | Phase 4 | 178 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization[NCT03889574] | 84 participants (Actual) | Observational | 2019-02-26 | Completed | |||
| A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969] | Phase 4 | 2,200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Comparison of Accidents and Their Circumstances With Oral Anticoagulants. The CACAO Study[NCT02376777] | 4,162 participants (Actual) | Observational | 2014-04-30 | Completed | |||
| Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928] | Phase 3 | 200 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| Anticoagulant-associated Intracranial Hemorrhage: Patient Characteristics and Outcomes From National Institute of Neurology and Neurosurgery Manuel Velasco: Single-Center Observational Study[NCT06168838] | 1,200 participants (Anticipated) | Observational | 2023-08-09 | Recruiting | |||
| [NCT02937025] | Phase 1/Phase 2 | 154 participants (Anticipated) | Interventional | 2017-01-31 | Not yet recruiting | ||
| WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF)[NCT00129545] | Phase 2/Phase 3 | 800 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study[NCT04684212] | 2,931 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | |||
| Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients With Atrial Fibrillation (PRAGUE-17 Study)[NCT02426944] | Phase 4 | 400 participants (Anticipated) | Interventional | 2015-10-13 | Completed | ||
| Registry of Left Atrial Appendage Occlusion With WATCHMAN® Device in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic Kidney Disease on Hemodialysis[NCT03446794] | 300 participants (Actual) | Observational [Patient Registry] | 2018-03-14 | Completed | |||
| Feasibility and Prognostic Role of Percutaneous Left Atrial Appendage Closure in Patients With Heart Failure and Atrial Fibrillation at High Risk for Cerebrovascular Events[NCT04472871] | 300 participants (Anticipated) | Observational | 2020-07-20 | Not yet recruiting | |||
| A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00243178] | Phase 3 | 6,706 participants (Actual) | Interventional | 2003-07-31 | Terminated | ||
| PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy[NCT03392948] | 1,080 participants (Anticipated) | Observational [Patient Registry] | 2018-02-09 | Active, not recruiting | |||
| Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban[NCT05632445] | Phase 4 | 160 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
| Improvements of Hand Function in Chronic Stroke Related to Upper Arm Anesthesia[NCT00006414] | 12 participants | Observational | 2000-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Time to event analysis of patients with adjudicated all cause death. The number of observed patients with adjudicated all cause death was reported. All cause death is defined as the death from any cause included CV death, non-CV death, and undetermined cause of death. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 55 |
| Dabigatran Etexilate 150mg | 30 |
| Warfarin | 48 |
| Warfarin (Excluding Elder Patients Outside USA) | 35 |
"Time to event analysis of patients with adjudicated Cardiovascular (CV) death. The number of observed patients with adjudicated Cardiovascular (CV) death was reported.~CV death included death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to CV procedures, death due to CV haemorrhage, and death due to other CV causes." (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 37 |
| Dabigatran Etexilate 150mg | 21 |
| Warfarin | 31 |
| Warfarin (Excluding Elder Patients Outside USA) | 24 |
"Time to event analysis of patients with adjudicated Non-cardiovascular (Non-CV). The number of observed patients with adjudicated Non-CV was reported.~Non-CV death was defined as any death with a specific cause that was not thought to be CV. These were possible examples of non-CV causes of death: Pulmonary, Renal, Gastrointestinal, Hepatobiliary, Pancreatic Infection(included sepsis), Inflammatory (e.g. systemic inflammatory response syndrome) or immune (including autoimmune), Haemorrhage that was neither CV bleeding nor a stroke, Non-CV procedure or surgery, Trauma, Suicide, Non-prescription drug reaction or overdose, Prescription drug reaction or overdose, Neurological (non-CV), Malignancy, Other non-CV" (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 14 |
| Dabigatran Etexilate 150mg | 4 |
| Warfarin | 13 |
| Warfarin (Excluding Elder Patients Outside USA) | 8 |
"Time to event analysis of patients with adjudicated Undetermined cause of death. The number of observed patients with adjudicated Undetermined cause of death was reported.~This is referred to a death not attributable to cardiovascular (CV) death or to a non-cardiovascular (non-CV) cause. Inability to classify the cause of death may have been due to lack of information (e.g. the only available information was patient died) or when there was insufficient supporting information or detail to assign the cause of death." (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 4 |
| Dabigatran Etexilate 150mg | 5 |
| Warfarin | 4 |
| Warfarin (Excluding Elder Patients Outside USA) | 3 |
Time to event analysis of patients with the composite endpoint of death + myocardial infarction (MI) + stroke. The number of observed patients with the composite endpoint of death + myocardial infarction (MI) + stroke was reported. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 107 |
| Dabigatran Etexilate 150mg | 60 |
| Warfarin | 80 |
| Warfarin (Excluding Elder Patients Outside USA) | 57 |
Time to event analysis of patients with composite endpoint of death or first thrombotic event (all death, myocardial infarction (MI), stroke/systemic embolism (SE)). The number of observed patients with composite endpoint of death or thrombotic event (all death, MI, stroke/SE). (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 108 |
| Dabigatran Etexilate 150mg | 60 |
| Warfarin | 83 |
| Warfarin (Excluding Elder Patients Outside USA | 60 |
| All Dabigatran Etexilate | 168 |
Time to event analysis of patients with death or thrombotic event (all death, myocardial infarction, stroke/systemic embolism) or unplanned revascularisation by Percutaneous Coronary Intervention/Coronary Artery Bypass Graft. The number of observed patients with death or first thrombotic event or unplanned revascularisation by PCI/CABG was reported. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 149 |
| Dabigatran Etexilate 150mg | 90 |
| Warfarin | 131 |
| Warfarin (Excluding Elder Patients Outside USA) | 98 |
| All Dabigatran Etexilate | 239 |
"Time to event analysis of patients with first adjudicated International Society of Thrombosis and Haemostasis (ISTH) Major Bleeding Event (MBE) or Clinically Relevant Non Major Bleeding Event (CRNMBE). The number of observed patients with adjudicated ISTH MBE or CRNMBE was reported.~Full analysis set (FAS): All consenting patients randomised were analysed in the treatment group to which they were randomised regardless of whether they took trial medication. The start date of the observation period for this analysis set was the date of randomisation. Patients who discontinued trial medication were followed until the end of the trial.~Patients who were lost to follow-up for vital status were censored for the primary endpoint at the time of their last known vital status.~Intention to treat period: The observation period for these analysis was the so called 'intention to treat period'." (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 151 |
| Dabigatran Etexilate 150mg | 154 |
| Warfarin | 264 |
| Warfarin (Excluding Elder Patients Outside USA) | 196 |
Time to event analysis of patients with first adjudicated Myocardial Infarction (MI). The number of observed patients with adjudicated MI was reported (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 44 |
| Dabigatran Etexilate 150mg | 26 |
| Warfarin | 29 |
| Warfarin (Excluding Elder Patients Outside USA) | 22 |
"Time to event analysis of patients with first adjudicated Systemic embolism (SE). The number of observed patients with adjudicated SE was reported.~SE is an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts) and had to be documented by angiography, surgery, scintigraphy, or autopsy." (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 3 |
| Dabigatran Etexilate 150mg | 1 |
| Warfarin | 3 |
| Warfarin (Excluding Elder Patients Outside USA) | 3 |
Time to event analysis of patients with first adjudicated Stent Thrombosis (ST). The number of observed patients with adjudicated ST was reported. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 15 |
| Dabigatran Etexilate 150mg | 7 |
| Warfarin | 8 |
| Warfarin (Excluding Elder Patients Outside USA) | 7 |
"Time to event analysis of patients with first adjudicated Stroke. The number of observed patients with adjudicated Stroke was reported.~Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction" (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 17 |
| Dabigatran Etexilate 150mg | 9 |
| Warfarin | 13 |
| Warfarin (Excluding Elder Patients Outside USA) | 8 |
Time to event analysis of patients with adjudicated unplanned revascularisation by Percutaneous Coronary Intervention (PCI)/Coronary Artery Bypass Graft (CABG). The number of observed patients with adjudicated unplanned revascularisation by PCI/CABG was reported. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 76 |
| Dabigatran Etexilate 150mg | 51 |
| Warfarin | 69 |
| Warfarin (Excluding Elder Patients Outside USA) | 52 |
Clinically significant bleeding is a composite of Thrombolysis in Myocardial Infarction (TIMI) major bleeding, minor bleeding, and bleeding requiring medical attention (BRMA). TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of greater than or equal to (>=) 5 grams per deciliter (g/dL) (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of >=15 percent (%)). TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to less than (<) 5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to <15 percent). A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event. (NCT01830543)
Timeframe: Up to Month 12
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 15 mg | 15.7 |
| Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | 16.6 |
| Vitamin K Antagonist (VKA) | 24.0 |
A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event. (NCT01830543)
Timeframe: Up to Month 12 and end of DAPT-Month 1, 6 and 12
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Up to Month 12 (n= 696, 706, 697) | End of DAPT-1 Month (n= 0, 108, 113) | End of DAPT-6 Month (n= 0, 248, 243) | End of DAPT-12 Month (n= 0, 350, 341) | |
| Rivaroxaban 15 mg | 13.4 | NA | NA | NA |
| Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | 14.4 | 16.7 | 12.9 | 14.9 |
| Vitamin K Antagonist (VKA) | 19.9 | 18.6 | 23 | 18.2 |
The percentage of participants with the first occurrence of cardiovascular death were evaluated. (NCT01830543)
Timeframe: Up to Month 12 and end of DAPT-Month 1, 6 and 12
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Up to Month 12 (n= 694, 704, 695) | End of DAPT-1 Month (n= 0, 108, 112) | End of DAPT-6 Month (n= 0, 248, 243) | End of DAPT-12 Month (n= 0, 348, 340) | |
| Rivaroxaban 15 mg | 2.2 | NA | NA | NA |
| Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | 2 | 1.9 | 2.4 | 1.7 |
| Vitamin K Antagonist (VKA) | 1.6 | 1.8 | 1.6 | 1.5 |
Percentage of participants who experienced adverse cardiovascular events (cardiovascular death, myocardial Infarction (MI) and stroke) collectively, were assessed. (NCT01830543)
Timeframe: Up to Month 12 and end of DAPT-Month 1, 6 and 12
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Up to Month 12 (n= 694, 704, 695) | End of DAPT-1 Month (n= 0, 108, 112) | End of DAPT-6 Month (n= 0, 248, 243) | End of DAPT-12 Month (n= 0, 348, 340) | |
| Rivaroxaban 15 mg | 5.9 | NA | NA | NA |
| Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | 5.1 | 5.6 | 6.5 | 4 |
| Vitamin K Antagonist (VKA) | 5.2 | 4.5 | 3.7 | 6.5 |
The percentage of participants with the first occurrence of Myocardial Infarction were evaluated. (NCT01830543)
Timeframe: Up to Month 12 and end of DAPT-Month 1, 6 and 12
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Up to Month 12 (n= 694, 704, 695) | End of DAPT-1 Month (n= 0, 108, 112) | End of DAPT-6 Month (n= 0, 248, 243) | End of DAPT-12 Month (n= 0, 348, 340) | |
| Rivaroxaban 15 mg | 2.7 | NA | NA | NA |
| Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | 2.4 | 2.8 | 2.8 | 2 |
| Vitamin K Antagonist (VKA) | 3 | 0.9 | 2.5 | 4.1 |
The percentage of participants with the first occurrence of stent thrombosis were evaluated. (NCT01830543)
Timeframe: Up to Month 12 and end of DAPT-Month 1, 6 and 12
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Up to Month 12 (n= 694, 704, 695) | End of DAPT-1 Month (n= 0, 108, 112) | End of DAPT-6 Month (n= 0, 248, 243) | End of DAPT-12 Month (n= 0, 348, 340) | |
| Rivaroxaban 15 mg | 0.7 | NA | NA | NA |
| Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | 0.9 | 1.9 | 1.6 | 0 |
| Vitamin K Antagonist (VKA) | 0.6 | 0.9 | 0.4 | 0.6 |
The percentage of participants with the first occurrence of Stroke were evaluated. (NCT01830543)
Timeframe: Up to Month 12 and end of DAPT-Month 1, 6 and 12
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Up to Month 12 (n= 694, 704, 695) | End of DAPT-1 Month (n= 0, 108, 112) | End of DAPT-6 Month (n= 0, 248, 243) | End of DAPT-12 Month (n= 0, 348, 340) | |
| Rivaroxaban 15 mg | 1.2 | NA | NA | NA |
| Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | 1.4 | 1.9 | 2.4 | 0.6 |
| Vitamin K Antagonist (VKA) | 1 | 2.7 | 0 | 1.2 |
TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, Clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of >= 5 g/dL (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of >=15 percent). (NCT01830543)
Timeframe: Up to Month 12 and end of DAPT-Month 1, 6 and 12
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Up to Month 12 (n= 696, 706, 697) | End of DAPT-1 Month (n= 0, 108,113) | End of DAPT-6 Month (n= 0, 248,243) | End of DAPT-12 Month (n= 0, 350,341) | |
| Rivaroxaban 15 mg | 2.0 | NA | NA | NA |
| Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | 1.7 | 0.9 | 2.8 | 1.1 |
| Vitamin K Antagonist (VKA) | 2.9 | 4.4 | 3.7 | 1.8 |
TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to <5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to <15 percent). (NCT01830543)
Timeframe: Up to Month 12 and end of DAPT-Month 1, 6 and 12
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Up to Month 12 (n= 696, 706, 697) | End of DAPT-1 Month (n= 0, 108, 113) | End of DAPT-6 Month (n= 0, 248, 243) | End of DAPT-12 Month (n= 0, 350, 341) | |
| Rivaroxaban 15 mg | 1.0 | NA | NA | NA |
| Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | 1.0 | 0.9 | 0.4 | 1.4 |
| Vitamin K Antagonist (VKA) | 1.9 | 1.8 | 2.5 | 1.5 |
The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug). (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 251 |
| Placebo + ASA | 162 |
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 825 |
| Placebo + ASA | 841 |
The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 296 |
| Placebo + ASA | 408 |
"The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up :~stroke (nonfatal or fatal)~myocardial infarction (nonfatal or fatal)~non-CNS systemic embolism~vascular death~The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group." (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| All components | - Myocardial Infarction (fatal or not) | - Stroke (fatal or not) | - Non-CNS systemic embolism | - Vascular death | |
| Clopidogrel + ASA | 832 | 84 | 285 | 50 | 413 |
| Placebo + ASA | 924 | 105 | 391 | 48 | 380 |
A Bayesian model allowed for sequential evaluation of the primary endpoints, event rates reported per 100 patient-years (calculated as 100*N events/Total patient-years) (NCT00129545)
Timeframe: 5 years
| Intervention | events per 100 pt yrs (Number) |
|---|---|
| Implantable Device | 2.2 |
| Warfarin Control | 3.7 |
Implant procedure success is defined as the delivery and release of a WATCHMAN Device into the LAA. (NCT00129545)
Timeframe: Initial implant procedure
| Intervention | percentage of implant attempts (Number) |
|---|---|
| WATCHMAN | 90.9 |
Serious bleeding events evaluated by the Clinical Events Committee included pericardial effusion requiring drainage, cranial bleeding events due to any source, gastrointestinal bleeds requiring transfusion, and any bleeding related to the device or procedure that necessitates an operation. (NCT00129545)
Timeframe: 5 years
| Intervention | Events per 100 pt-yrs (Number) |
|---|---|
| Implantable Device | 3.5 |
| Warfarin Control | 3.2 |
47 reviews available for ticlopidine and Atrial Fibrillation
| Article | Year |
|---|---|
Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2017 |
Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2017 |
[Impact of different antithrombotic therapy strategy on prognosis in coronary heart disease patients combining with atrial fibrillation: a meta analysis].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Fibrinolytic Agents; He | 2017 |
Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clopidogrel; Drug Administration Schedule | 2018 |
Triple therapy (aspirin, clopidogrel and oral anticoagulant) after percutaneous coronary intervention: another call for personalized medicine.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi | 2013 |
Pharmacokinetic considerations for antithrombotic therapies in stroke.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Factor | 2013 |
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dru | 2014 |
Combining antiplatelet and antithrombotic therapy (triple therapy): what are the risks and benefits?
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibri | 2014 |
Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2014 |
Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Percutaneous Coronary Interventio | 2014 |
Effect of addition of clopidogrel to aspirin on subdural hematoma: meta-analysis of randomized clinical trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; | 2015 |
Patients with atrial fibrillation undergoing percutaneous coronary intervention. Current concepts and concerns: part I.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Female; Fibrinolytic Agents; He | 2015 |
Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Drug | 2015 |
New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Combinati | 2015 |
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi | 2008 |
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi | 2008 |
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi | 2008 |
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi | 2008 |
Optimizing antiplatelet therapy in high-risk patients with atrial fibrillation: insights from Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE A).
Topics: Antihypertensive Agents; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Cardiovascular Diseases; | 2009 |
Modern role for clopidogrel in management of atrial fibrillation and stroke reduction.
Topics: Age Factors; Atrial Fibrillation; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregatio | 2010 |
[New aspects on "triple therapy" after coronary stent implantation].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; | 2010 |
Triple therapy in hospitalized patients: facts and controversies.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio | 2011 |
Clopidogrel hydrogen sulphate for atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Platel | 2011 |
New insights in antiplatelet therapy for patients with ischemic stroke.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; I | 2011 |
[Clopidogrel and stroke].
Topics: Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Inflamm | 2011 |
Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Brain Ischemia; Clopidogrel; | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogr | 2012 |
Impact of antiplatelet therapy in heart disease.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio | 2012 |
Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Hemorr | 2012 |
Challenges in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, C | 2012 |
Preventing stroke in patients with atrial fibrillation: current treatments and new concepts.
Topics: Aspirin; Atrial Appendage; Atrial Fibrillation; Azetidines; Benzylamines; Clopidogrel; Dipyridamole; | 2003 |
Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Combinations; Evidence-Based Medicine; Humans; Plate | 2003 |
Trials of newer approaches to anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Clopidogrel; Humans; Interna | 2004 |
Atrial fibrillation: should we target platelets or the coagulation pathway?
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk Assessment; | 2003 |
Preparing for the post-warfarin generation of antithrombotics.
Topics: Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clopidogrel; Fibrinolytic Agents; Fon | 2004 |
New possibilities in anticoagulant management of atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Clopidogrel; Humans; Oligosa | 2004 |
Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Pressur | 2005 |
[Preventing cerebrovascular accidents during atrial fibrillation].
Topics: Administration, Oral; Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conver | 2005 |
[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; | 2005 |
Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Admi | 2006 |
Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clinical Tri | 2008 |
Antiplatelet therapy for stroke prevention.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel | 2007 |
Medical treatment for stroke prevention.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard | 1994 |
Antithrombotic therapies for stroke prevention.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Fibrinolyti | 1994 |
[Antithrombotic agents and prevention of cerebrovascular accidents].
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clopidogrel; Echocardiography; Humans; Intr | 1996 |
[A case of mobile left atrial thrombus without mitral valve disease].
Topics: Aged; Atrial Fibrillation; Cardiac Surgical Procedures; Female; Fibrinolytic Agents; Heart Atria; He | 1997 |
Antiplatelet agents and stroke prevention.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Clopidogrel; Dipy | 1998 |
Stroke: part I. A clinical update on prevention.
Topics: Aspirin; Atrial Fibrillation; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; | 1999 |
[Cholestatic hepatitis as a rare side effect of therapy with ticlopidine].
Topics: Aged; Atrial Fibrillation; Biopsy, Needle; Chemical and Drug Induced Liver Injury; Cholestasis; Chro | 2000 |
[Prevention of recurrence in cerebral infarction].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cerebral Infarction; Drug Therapy, C | 2002 |
29 trials available for ticlopidine and Atrial Fibrillation
128 other studies available for ticlopidine and Atrial Fibrillation
| Article | Year |
|---|---|
Influence of Clinically Significant Genes on Antiplatelet Effect of Clopidogrel and Clinical Outcomes in Patients with Acute Coronary Syndrome and Atrial Fibrillation.
Topics: Acute Coronary Syndrome; Aryldialkylphosphatase; Atrial Fibrillation; Clopidogrel; Cytochrome P-450 | 2022 |
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Coronary A | 2017 |
WATCHMAN device-related thrombus successfully treated with apixaban: A case report.
Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Factor Xa Inhibit | 2017 |
Left ventricular mural thrombus despite treatment with dabigatran and clopidogrel.
Topics: Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Clopidogrel; Dabigatran; Diag | 2018 |
Amplatzer left atrial appendage occlusion: single center 10-year experience.
Topics: Aged; Aged, 80 and over; Anesthesia, Local; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac | 2013 |
PCI patients taking oral anticoagulants may not need aspirin.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Clopidogrel; Drug Therapy, Combination | 2013 |
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)].
Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; | 2013 |
Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2013 |
Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Clopidogrel; Dru | 2013 |
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2013 |
The place of newer oral anticoagulants in the treatment of patients with non-valvular atrial fibrillation and coronary artery disease.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Dis | 2013 |
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulation; Clopidogrel; Co | 2014 |
Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; China; Clopidogrel; Cost-Benefit Analysis; Drug Therap | 2014 |
Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Thera | 2014 |
Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; | 2014 |
Lower gastrointestinal bleeding associated with diclofenac topical patch in a patient with colonic mass and on antiplatelet therapy for atrial fibrillation.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Atrial Fibrillation; Clopidogrel; Colonic Neoplasms; | 2014 |
Intracranial hemorrhage during dual antiplatelet therapy after percutaneous left atrial appendage closure.
Topics: Aged; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti | 2014 |
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogr | 2015 |
Triple therapy for atrial fibrillation and ACS with or without PCI: don't drop aspirin just yet.
Topics: Aspirin; Atrial Fibrillation; Humans; Percutaneous Coronary Intervention; Ticlopidine; Vitamin K | 2015 |
Reply: Triple therapy for atrial fibrillation and ACS with or without PCI: don't drop aspirin just yet.
Topics: Aspirin; Atrial Fibrillation; Humans; Percutaneous Coronary Intervention; Ticlopidine; Vitamin K | 2015 |
[Paroxysmal atrial fibrillation well controlled. Why the sudden patient syncope?].
Topics: Amiodarone; Atrial Fibrillation; Clopidogrel; Coronary Disease; Diagnosis, Differential; Drug Therap | 2015 |
Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.
Topics: Aged; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Databases, Factual; Female; Fibrinolyti | 2015 |
Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Case-Control Studies; Clopido | 2015 |
Antithrombotic therapy in patients undergoing TAVI with concurrent atrial fibrillation. One center experience.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Aortic Valve Stenosis; Atrial Fibrillation; Clopidogrel; Fem | 2015 |
Association of rivaroxaban anticoagulation and spontaneous vitreous hemorrhage.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Clopidogrel; Factor Xa Inhibitors; Hum | 2015 |
[SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2015 |
Anti-platelet pre-treatment for atrial fibrillation patients on warfarin referred for coronary angiography/stenting because of non-ST-elevation acute coronary syndrome: An alternative proposal.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Atrial Fibrillation; Clopidogrel; Coronary Angiogr | 2015 |
Underutilisation of Guideline-based Therapy Primary Prevention among Patients Presenting with AF-related Ischaemic Stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; | 2015 |
A new approach: Left atrial appendage occlusion, as an alternative to anticoagulant, to treat patient who suffered of atrial fibrillation, acute coronary syndrome and clopidogrel resistance.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Clopidogrel; D | 2016 |
Percutaneous left atrial appendage occlusion: Device thrombosis in clopidogrel non-responders.
Topics: Aged; Aged, 80 and over; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Female; Heart Diseases; | 2016 |
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; | 2016 |
Impact of Triple Therapy in Elderly Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Female; Humans; | 2016 |
Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Surgical Procedures; Clopido | 2016 |
Another side effect of ticagrelor: Atrial fibrillation.
Topics: Adenosine; Aged; Angina, Unstable; Atrial Fibrillation; Clopidogrel; Humans; Male; Ticagrelor; Ticlo | 2016 |
Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2017 |
Locked Away: Percutaneous Closure of a Malignant Left Atrial Appendage to Constrain an Unresolvable Thrombus.
Topics: Aged; Aspirin; Atrial Appendage; Atrial Fibrillation; Catheter Ablation; Clopidogrel; Combined Modal | 2016 |
Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience.
Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebra | 2016 |
The Triple Challenge of Triple Therapy.
Topics: Anticoagulants; Atrial Fibrillation; Drug Therapy, Combination; Platelet Aggregation Inhibitors; Tic | 2016 |
Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Clopidogrel; Dabigatran | 2016 |
Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation-a cohort study in primary care.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; | 2017 |
Atrial Fibrillation and PCI - Do We Still Need Aspirin?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Platelet Aggregatio | 2016 |
Percutaneous left atrial appendage closure followed by single antiplatelet therapy: Short- and mid-term outcomes.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Cl | 2017 |
Ticagrelor, but not clopidogrel active metabolite, displays antithrombotic properties in the left atrial endocardium.
Topics: Adenosine; Antithrombins; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Endocardium; Heart Atr | 2017 |
Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; As | 2008 |
Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspir | 2008 |
The ACTIVE pursuit of stroke prevention in patients with atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation I | 2009 |
ACTIVE A: balancing the benefits and risks of clopidogrel and aspirin.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Humans; Intracra | 2009 |
[Clopidogrel in the treatment of atrial fibrillation: comparison with warfarin. The results of ACTIVE W trial].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Dose-Response Relationship, Drug; Follow-Up | 2009 |
Prevention of stroke in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; | 2009 |
[Cardiology 2009].
Topics: Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Cardiology; Cardiovascular Diseases; Clopidogrel | 2009 |
[ASS plus clopidogrel in contraindication for marcumar].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Contraindications; Drug Therapy, Combinat | 2009 |
Who is ineligible for warfarin in atrial fibrillation?
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Contraindications; Drug Therapy, Combinat | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Myocardial I | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Costs; Drug Therapy, Combination; Humans; Platelet A | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Pla | 2009 |
Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atri | 2009 |
Pro: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; | 2009 |
Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clinica | 2009 |
By the way, doctor. I am currently on Coumadin because I had atrial fibrillation after my bypass, Plavix because of my stent, and a baby aspirin. Why do I need to take three blood thinners?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiopulmonary Bypass; Clopidogrel; Humans; Platelet | 2009 |
Aspirin gets a backup against atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation I | 2009 |
Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Brain Ischemia; Clini | 2009 |
[Abdominal tumor after persistent coughing and uncontrolled anticoagulation].
Topics: Abdomen, Acute; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coloni | 2010 |
Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor | 2010 |
[Cardiac workup after cerebral ischemia. Consensus paper of the Working Group on Heart and Brain of the German Cardiac Society and German Stroke Society].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; | 2010 |
Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Dis | 2010 |
[Balancing act in antithrombotic therapy. Between hemorrhage and embolism].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Coronar | 2010 |
Role of triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents.
Topics: Algorithms; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Vessels; Drug Therapy, Combination; | 2010 |
[Perioperative use of antithrombotic agents: recommendations of the American College of Chest Physicians (ACCP) and the French Superior Health Authority (HAS)].
Topics: Anticoagulants; Atrial Fibrillation; Cardiac Surgical Procedures; Clopidogrel; Fibrinolytic Agents; | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Ischaemic stroke--prevention is better than cure.
Topics: Adult; Age Factors; Aged; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Blo | 2010 |
CYP2C19 genotype and outcomes of clopidogrel treatment.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Clopidogrel; Cytochrome | 2011 |
Atrial fibrillation, is warfarin the only option for stroke prevention?
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Atrial Fibrillation; Biphenyl Compounds; Cl | 2011 |
Atrial fibrillation, is warfarin the only option for stroke prevention?
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Comp | 2011 |
Dual antiplatelet therapy and the risk of bleeding.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhag | 2011 |
The unmet need of patients with atrial fibrillation: AVERROES and the novel oral anticoagulants.
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Comp | 2011 |
Atrial fibrillation treatment update.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Heart Rate; Humans; Platelet Aggregation Inhibitors; Prac | 2011 |
Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Femal | 2011 |
Thrombus formation on a left atrial appendage closure device.
Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Equipment Design; | 2011 |
Clinical update on nursing home medicine: 2011.
Topics: Anti-Ulcer Agents; Anticoagulants; Atrial Fibrillation; Clopidogrel; Clostridioides difficile; Delir | 2011 |
Selecting the optimal stroke prevention therapy in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhib | 2011 |
Antiplatelet and anticoagulant therapy in patients with gastrointestinal bleeding: an 86-year-old woman with peptic ulcer disease.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Interaction | 2011 |
Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Cohort St | 2012 |
Warfarin use in nursing home residents: results from the 2004 national nursing home survey.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cross-Sectional | 2012 |
[Pharmacoeconomic analysis of dabigatran etexilate effectiveness in patients with nonvalvular atrial fibrillation].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation T | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrilla | 2012 |
Paraoxonase 1 Q192R variant and clopidogrel efficacy: fact or fiction?
Topics: Angina, Unstable; Aryldialkylphosphatase; Atrial Fibrillation; Clopidogrel; Female; Humans; Male; Po | 2012 |
Triple antithrombotic therapy after coronary stenting in the elderly with atrial fibrillation: necessary or too hazardous?
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet A | 2012 |
Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dose-Response Relat | 2012 |
Clopidogrel in atrial fibrillation: is there any justification now in the era of new anticoagulants?
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Practice Guideli | 2012 |
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh | 2012 |
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazo | 2012 |
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fi | 2012 |
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor | 2012 |
[Expert answer. Coronary artery patients with atrial fibrillation on anticoagulation treatment may need antithrombotic treatment. What kind is there?].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2012 |
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidaz | 2012 |
The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Case-Control Studies; Clopidogrel; Cohort Studies; Drug Therapy, Combinat | 2013 |
Stroke prevention in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Prescriptions; Female; F | 2003 |
Embolic attack in patients with atrial fibrillation and atrial thrombus depends on the character of the thrombus.
Topics: Aged; Aspirin; Atrial Fibrillation; Disease-Free Survival; Drug Therapy, Combination; Echocardiograp | 2003 |
[Anticoagulation and antiaggregation in cardiac patients].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Clo | 2003 |
Spontaneous pharyngeal haemorrhage in the anticoagulated patient.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Hemorrhage; Humans; Male; Pharyngeal Disease | 2003 |
Elective coronary angiography and percutaneous coronary intervention during uninterrupted warfarin therapy.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Atrial Fibrillation; Cardia | 2003 |
Proximal deep venous thrombosis occurring after sudden clopidogrel suspension.
Topics: Aged; Atrial Fibrillation; Clopidogrel; Humans; Male; Platelet Aggregation Inhibitors; Prognosis; Su | 2004 |
Clopidogrel-aspirin combination for atrial fibrillation: CLAAF is not CLEAR.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase II as Topic; Clopidogrel; Drug | 2005 |
Clopidogrel as antithrombotic therapy in atrial fibrillation.
Topics: Atrial Fibrillation; Atrial Flutter; Clopidogrel; Electric Countershock; Evidence-Based Medicine; Fi | 2005 |
[Prophylaxis of stroke].
Topics: Age Factors; Aged; Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fi | 2005 |
[Even in 60-year-old atrial fibrillation is not uncommon. Advances in long-term treatment].
Topics: Administration, Oral; Age Factors; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillat | 2006 |
Good old warfarin for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Pla | 2006 |
Saddle embolism after corrective femoral osteotomy: a case report.
Topics: Arterial Occlusive Diseases; Atrial Fibrillation; Echocardiography, Transesophageal; Embolectomy; Em | 2006 |
Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio | 2006 |
Prevention of vascular events in atrial fibrillation.
Topics: Accidental Falls; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggreg | 2007 |
Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio | 2007 |
[Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atrial Fibrillation; Bipheny | 2007 |
Triple antithrombotic therapy with aspirin, clopidogrel and warfarin--a persisting dilemma.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Fibrinoly | 2007 |
Treatment in a haemophiliac A patient with paroxysmal atrial fibrillation and ischemic heart disease.
Topics: Anticoagulants; Atrial Fibrillation; Clopidogrel; Follow-Up Studies; Hemophilia A; Heparin; HIV Infe | 2007 |
Post-stenting antithrombotic drug therapy in patients with atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Fibrinolytic Agents; Humans; Practice Guidelines as Topic | 2007 |
Guidelines for medical treatment for stroke prevention. American College of Physicians.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard | 1994 |
Clinical safety and efficacy of clopidogrel--implications of the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study for future management of atherosclerotic disease.
Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Humans; Myocardial Infa | 1998 |
[Atrial fibrillation and thromboembolism: a multicenter cooperative study. Research Group for Antiarrhythmic Drug Therapy].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dipyridamole; Female; Heart Diseases; Humans; Male; Mi | 1998 |
Sex differences and similarities in the management and outcome of stroke patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Comorbidity; | 2000 |
Antiplatelet drugs in cardiovascular prevention: stroke: acute phase and secondary prevention.
Topics: Anticoagulants; Arrhythmia, Sinus; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Dipyridamole | 2000 |
Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; | 2001 |
Platelet aggregation behaviour in patients treated with ticlopidine.
Topics: Adult; Aged; Aspirin; Atrial Fibrillation; Bleeding Time; Dipyridamole; Female; Humans; Male; Middle | 1987 |